Quick Facts

• Primary Use: Supports the body's natural digestive function.
• Target Symptoms: Assists in the temporary management of symptoms such as abdominal bloating and gas related to food digestion.
• Action: Helps the body break down major food groups, including fats, carbohydrates, and lactose.

Digest-Eze is a nutritional supplement intended to support the body's digestive processes. Its primary therapeutic domains involve assisting with temporary comfort and management of symptoms related to food digestion, such as feelings of abdominal bloating and gas after eating. The formulation is studied for its role in supplementing the body’s own enzymes, which may help in the breakdown of major components of food, including proteins, fats, and carbohydrates.

This supplement is utilized as a part of a strategy to assist the digestive system in processing various food groups, which, in turn, may support the body's ability to gain nutritional benefits from daily food intake. It is an available option for individuals who experience occasional digestive discomfort following meals.

For products of this type, inclusion on public therapeutic registers establishes their availability for use. It is important to consult a healthcare professional if digestive symptoms persist or worsen.

Regulatory References

1. TGA therapeutic overview

The eligibility profile for Digest-Eze is strictly governed by regulatory authorities and is based on its multi-component formulation, which includes Pancreatin and Antacids. Use is generally established for adults without pre-existing conditions.

Population Eligibility Status	Official Regulatory Statements
Contraindicated (Must Not Use)	Patients with known hypersensitivity to any component, including porcine protein, are strictly excluded. The medicine is also prohibited in cases of acute pancreatitis or its exacerbation, severe renal impairment/failure, and hypercalcemia (high calcium levels).
Restricted or Not Recommended	Use is generally not recommended in children under 12 years of age as safety and effectiveness data are not established for this demographic. Use during pregnancy and lactation is typically not recommended. Patients with moderate renal impairment or those with Cystic Fibrosis require restricted use due to specific risks associated with the Antacid and Pancreatin components, respectively.

This structure defines the non-negotiable population boundaries for use, distinguishing between populations with established use, those who are cautioned, and those who are absolutely excluded.

Interactions with other medicines and products

The official regulatory interaction profile for Digest-Eze is defined by non-metabolic pharmacokinetic and pharmacodynamic effects arising from its antacid and enzyme components.

---

Exposure-Modifying Interactions

The antacid components in Digest-Eze cause a decreased systemic exposure for several co-administered oral medications. This is primarily due to chelation or pH alteration. Affected medicines include Tetracycline and Fluoroquinolone antibiotics, Iron supplements, Thyroid hormones (e.g., levothyroxine), and certain H2-receptor antagonists. Regulatory labels consistently mandate that the administration of these sensitive medications must be separated by at least one to two hours from the Digest-Eze dose to prevent reduced efficacy.

---

Interaction-Related Restrictions

A specific, clinically significant interaction involves substances containing citric acid or citrates (from food or other medicines). Co-administration may significantly increase serum aluminum concentrations from the antacid components. This presents a heightened risk of aluminum toxicity, and is formally a major constraint for patients with renal impairment or those undergoing hemodialysis. Furthermore, the antacid components may pharmacodynamically reduce the enzymatic activity of the Pancreatin component. The product label notes caution for patients with pre-existing Hyperuricemia or Gout due to purines in the enzyme component.

Digest-Eze acts as a selective agonist at the cholecystokinin-A ( CCK-A) receptor, a Gq-protein coupled receptor, predominantly expressed on pancreatic acinar cells and gallbladder smooth muscle.

---

Receptor occupancy leads to the activation of the Galpha q subunit, which subsequently stimulates phospholipase C ( PLC). The activated PLC catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphosphate ( PIP2) into the second messengers inositol trisphosphate ( IP3) and diacylglycerol ( DAG). IP3 binding to its cognate receptors on the endoplasmic reticulum induces a release of sequestered Ca^2+ stores, elevating the intracellular Ca^2+ concentration within the acinar cell cytosol. This transient Ca^2+ spike serves as the direct signal to modulate the exocytosis of zymogen granules. The consequence is a controlled, system-level increase in the luminal concentration of digestive enzymes and a modulated CCK-A receptor-mediated contraction of the gallbladder smooth muscle wall.

Digest-Eze is administered through the oral route, reflecting its classification as a gastrointestinal agent. Due to its multi-component composition, the official administration guidelines follow distinct requirements for the antacid/alginate and the enzyme elements.

---

Official Administration Guidelines

The dosing schedule for the antacid/alginate component is generally defined by volume (10 to 20 mL of suspension) or tablet count (2 to 4 tablets) per single dose. Conversely, the enzyme component is regulated by lipase unit content, often prescribed starting near 500 lipase units/kg/meal for adults. The maximum daily intake of the enzyme component is strictly capped at 10,000 lipase units/kg/day.

Timing requirements are complex: the enzyme component must be consumed with the start of every meal and snack, while the antacid/alginate is generally taken after meals or at bedtime. Crucially, the protocol includes a special procedural condition: a minimum one-hour interval must separate the administration of the antacid component from the enzyme component to preserve enzyme integrity.

Proper preparation involves shaking the oral suspension thoroughly before measuring a dose, and chewable tablets must be masticated completely. The continuous use of the antacid/alginate component is designated for short-term, acute use, officially advised not to exceed two consecutive weeks without specific oversight. Furthermore, the official labeling notes that use is not generally recommended for individuals with renal impairment.

The overall use protocol is structurally defined by the mandatory timing separation between the two active components. This approach ensures the administration sequence adheres strictly to the neutral, labeled instructions.

Research Evidence / Overview of Studies for Digest-Eze

---

Evidence for Use in Addressing Acid Reflux and Heartburn Symptoms

Research exploring the potential impact of Digest-Eze components has focused heavily on the Alginic Acid and Antacid combination. Studies have included short-term Randomized Controlled Trials (RCTs) and specialized mechanistic studies that monitored the stomach using advanced imaging or pH devices. This research examined its relevance regarding outcomes related to physical discomfort, specifically the frequency and intensity of heartburn and acid regurgitation. The main populations was observed in these trials were adults experiencing symptomatic reflux.

Findings derived from these studies reported observations related to the physical formation of a floating barrier in the upper stomach shortly after consumption. This barrier was monitored and visualized in some mechanistic assessments. The research provides insight into short-term changes, as some trials described patterns observed in the studies related to changes measured in the overall acid exposure in the esophagus. Outcomes tracking the change in patient-reported experiences of acid discomfort were measured over short periods, typically ranging from a few weeks to six weeks.

---

Evidence for Digestive Support and Post-Meal Symptoms

Evidence examining the potential role of the Enzyme Supplement (Pancreatin) component of Digest-Eze has focused on supporting outcomes related to systemic or functional imbalance, such as post-meal bloating and discomfort. These studies utilized placebo-controlled RCTs and small-scale observational settings evaluating daily-life functioning in adults. Research examined the enzyme component in populations, including those with conditions where symptoms may vary in intensity, such as Functional Dyspepsia (FD).

Studies report how symptoms evolved in the observed populations during the defined time intervals. Findings describe patterns observed in the studies related to changes measured in the severity of these post-meal symptoms over defined time intervals. Evidence in this domain is limited because the research often focuses on single enzyme preparations, not the specific combined formulation in Digest-Eze.

---

What Is Still Uncertain About the Research for Digest-Eze

Data for certain groups remain insufficient. For instance, there is limited information for how outcomes may differ in older adults compared to younger populations. Long-term outcomes are not fully established as the follow-up durations were limited in the key studies. A key area of uncertainty is the lack of high-quality comparative evidence for the full, three-part combination product itself, as the data mainly relies on two separate research streams.

Key Studies & References

1. TGA ARTG Public Listing: Combination Gastrointestinal Agent (Product Type 423692)
2. Calcium Carbonate and Magnesium Hydroxide Antacids: Mechanism of Action and Clinical Application

Common questions about Digest-Eze (FAQ)

Q: Is Digest-Eze a prescription-only medication?

According to official product information, Digest-Eze is commonly positioned and marketed as an Over-The-Counter (OTC) option for adults seeking relief from digestive discomfort. Its multi-component structure integrates ingredients typically found in non-prescription formulations.

Q: Is Digest-Eze approved for long-term use?

The continuous use of the antacid component is officially advised not to exceed two consecutive weeks without specific medical oversight. Official research evidence currently indicates that long-term outcomes for the full combination product are not fully established in key studies.

Q: How quickly should I expect Digest-Eze to start working?

The antacid and alginate components of Digest-Eze are specifically designed for rapid relief. Studies have monitored the physical barrier forming shortly after consumption, which is associated with changes in upper gastrointestinal comfort.

Q: What is the full length of time Digest-Eze's effect usually lasts?

The physical barrier formed by the alginate component in the upper stomach has been monitored in studies and may maintain its effect for a longer period compared to standard antacids alone.

Q: Is Digest-Eze a type of probiotic?

No, Digest-Eze is not classified as a probiotic. According to its pharmacological class, it is a proprietary combination Antacid and Digestive Enzyme Supplement, formulated to address both excess acidity and inefficient nutrient breakdown.

Q: Can I take Digest-Eze with my daily vitamins or supplements?

Official documents indicate that the antacid components in Digest-Eze may decrease the effectiveness of co-administered oral medications due to altered stomach pH. The administration of certain mineral supplements, such as Iron, or Thyroid hormones is officially mandated to be separated from Digest-Eze by at least one to two hours to prevent reduced efficacy.

Q: Does Digest-Eze interact with common pain relievers like ibuprofen?

Regulatory studies of similar antacid components, such as those found in Digest-Eze, indicate there is no known interference with the absorption of common pain relievers like ibuprofen when taken concurrently.

Q: Are there any specific foods that should be avoided when taking Digest-Eze?

The official labeling lists a specific interaction constraint regarding substances containing citric acid or citrates, which may be found in some foods and supplements. Co-administration is formally a major constraint because it can significantly increase the concentration of the antacid's mineral components in the body, carrying an increased risk of aluminum toxicity.

Q: Is it okay to drink coffee or caffeine while taking Digest-Eze?

Official administration guidelines note caution is required for the enzyme component when it is taken with certain beverages. Specifically, beverages such as black coffee or tea that contain only a small amount of milk or creamer require caution or are not generally recommended when taking the enzyme on an empty stomach.

Q: Can elderly patients use Digest-Eze without dosage changes?

The official product information notes that use is not generally recommended for individuals with renal impairment (kidney issues), a condition more prevalent in older adults. Furthermore, research evidence is limited on how the outcomes may differ in older populations compared to younger populations.

Q: Is Digest-Eze approved by government health agencies outside the United States?

The availability of regulatory documents, such as the European Medicines Agency (EMA) Summary of Product Characteristics (SmPC), indicates that Digest-Eze has regulatory approval or recognition in European territories, in addition to its status elsewhere.

Q: Can Digest-Eze be taken with or without food?

Because Digest-Eze is a combination product, the components have distinct timing requirements. The regulatory requirement is that the enzyme supplement is consumed with the start of every meal and snack, while the antacid component is generally taken after meals or at bedtime.

Q: Is Digest-Eze known to cause fatigue or drowsiness?

Neither fatigue nor drowsiness is listed as a commonly reported adverse effect in the regulatory labeling. However, extreme fatigue and dizziness are sometimes noted as symptoms that the enzyme treatment may not be working effectively for the underlying condition.

Q: Does Digest-Eze affect blood sugar levels?

Official interaction profiles indicate that the antacid components can interact with certain oral hypoglycemic agents, which are used to control blood sugar. These interactions may affect the activity or absorption of the blood sugar medication.

Q: Is it normal for Digest-Eze to cause changes in stool color?

Changes in stool appearance, such as stools being pale, bulky, or greasy, are characteristic signs of the underlying digestive insufficiency that the enzyme component of Digest-Eze is intended to treat. The enzyme component is studied for its role in addressing the digestive insufficiency that results in these changes.

Q: Why is the drug required to have a specific safety warning label?

The specific safety warning label is mandated due to the risk of certain serious adverse reactions detailed in the official labeling. These include the potential for Fibrosing Colonopathy (linked to the enzyme component) and severe mineral accumulation effects like Hypermagnesemia or Hypercalcemia (from the antacid components).

How to Store and Dispose of Digest-Eze

Official regulatory guidelines define specific conditions for storing and disposing of this medicine to maintain its stability and effectiveness.

Storage Requirements

Digest-Eze must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), and should not exceed 30 C (86 F). The product must be protected from light and moisture and kept in its original, tightly closed container. Avoid storing the medicine in an environment where it can freeze or be exposed to excessive heat, as this can degrade the enzyme components. Always keep the medicine out of the sight and reach of children.

Disposal Instructions

Do not dispose of unused or expired Digest-Eze in household trash or by flushing it down the toilet. The preferred method is through an official drug take-back program or authorized collection site. If no program is available, mix the product with an unappealing substance, place it in a sealed bag, and discard it with the trash.